

## Exploring Clinical Investigator Perspectives on the Optimal Management of Chronic Lymphocytic Leukemia (Hematology-Oncology Fellows)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Results from the Phase III ECOG-E1912 study, comparing ibrutinib/rituximab (IR) followed by maintenance ibrutinib to FCR (fludarabine/cyclophosphamide/rituximab) for patients aged 70 years or younger with previously untreated chronic lymphocytic leukemia (CLL), demonstrated a statistically significant improvement in progression-free survival (PFS) with IR in which subgroup?
  - a. Patients with IGHV mutations
  - b. Patients with no IGHV mutations**
2. Which of the following conclusions best summarizes the PFS findings from the Phase III Alliance A041202 study evaluating ibrutinib alone versus IR or bendamustine/rituximab (BR) for older patients with previously untreated CLL?
  - a. Only IR was superior to BR
  - b. BR was superior to IR
  - c. BR was superior to ibrutinib alone
  - d. Ibrutinib alone and IR were both superior to BR**
3. Which of the following drug descriptions best characterizes the mechanism of action of venetoclax?
  - a. Anti-CD20 monoclonal antibody
  - b. Bcl-2 inhibitor**
  - c. BTK inhibitor
4. The Phase III ELEVATE-TN trial comparing acalabrutinib alone or in combination with obinutuzumab to chlorambucil/obinutuzumab for patients with previously untreated CLL demonstrated which of the following efficacy outcomes?
  - a. Significant improvement in PFS with acalabrutinib monotherapy but not with acalabrutinib/obinutuzumab versus chlorambucil/obinutuzumab
  - b. Significant improvement in PFS with acalabrutinib/obinutuzumab but not with acalabrutinib monotherapy versus chlorambucil/obinutuzumab
  - c. Significant improvement in PFS in both acalabrutinib-containing arms versus chlorambucil/obinutuzumab**
5. Results of the Phase III CLL14 study demonstrated improved outcomes with which regimen compared to chlorambucil/obinutuzumab for patients with previously untreated CLL and coexisting medical conditions?
  - a. Venetoclax/rituximab
  - b. Venetoclax/obinutuzumab**
  - c. Bendamustine/obinutuzumab